WP-30
30-residue antiplatelet peptide from Whitmania pigra selectively inhibiting thrombin-induced platelet aggregation — Liu 2016 demonstrates rat arterio-venous shunt thrombosis attenuation.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- 30-residue antiplatelet peptide from Whitmania pigra selectively inhibiting thrombin-induced platelet aggregation — Liu 2016 demonstrates rat arterio-venous shunt thrombosis attenuation.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
WP-30's preclinical antithrombotic activity in rats does NOT establish clinical efficacy in humans. No FDA-approved derivative exists; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 3,100 Da
- Source species
- Whitmania pigra
- Discovered
- 2016 · Liu X et al.
Biological Targets
- → thrombin-induced platelet aggregation (selective; not ADP- or collagen-induced)
Key Citations
- Liu X et al. (2016), Biochem Biophys Res Commun · PMID 27021679
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.